Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.46 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | TEK | Q02763 | 4/20 | 0.46 |
| ▸ | MET | P08581 | 3/20 | 0.46 |
| ▸ | LCK | P06239 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22972321 | 0.90 | KDR (0.56) | KDRAURKATEKMETLCK | |
| SCHEMBL22971978 | 0.88 | POLB (0.49) | KDRAURKATEKMETLCK | |
| SCHEMBL22972196 | 0.88 | SORT1 (0.51) | KDRAURKATEKMETLCK | |
| SCHEMBL22972348 | 0.87 | POLB (0.47) | KDRAURKATEKMETLCK | |
| SCHEMBL22971946 | 0.86 | MAPT (0.48) | KDRAURKATEKMETLCK | |
| SCHEMBL22972029 | 0.86 | POLB (0.48) | KDRAURKATEKMETLCK | |
| SCHEMBL22971870 | 0.86 | POLB (0.48) | KDRAURKATEKMETPOLB | |
| SCHEMBL22971899 | 0.86 | POLB (0.48) | KDRAURKATEKMETLCK | |
| SCHEMBL22972316 | 0.85 | POLB (0.57) | POLBMAPK14MAPK1CYP3A4 | |
| SCHEMBL22972043 | 0.85 | KDR (0.58) | KDRAURKATEKMETLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2022-12-08 | — | — | US | disclosed |
| WO-2021023888-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABL1, PHKB, EEF2K | KDR 604/4885AURKA 245/4885TEK 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.